Evidence map›Paper›PMID 28693246›Full record

ArticleOncology letters2017

Genetic alterations in Japanese extrahepatic biliary tract cancer.

Rei Noguchi, Kiyoshi Yamaguchi, Tsuneo Ikenoue, Yumi Terakado, Yasunori Ohta, Naohide Yamashita, Osamu Kainuma, Sana Yokoi, Yoshiaki Maru, Hiroki Nagase and 1 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Overview of current targeted therapy in gallbladder cancer.Signal transduction and targeted therapy · 2020
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Rei NoguchiDivision of Clinical Genome Research, The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan.
Kiyoshi YamaguchiDivision of Clinical Genome Research, The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan.
Tsuneo IkenoueDivision of Clinical Genome Research, The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan.
Yumi TerakadoDivision of Clinical Genome Research, The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan.
Yasunori OhtaDepartment of Pathology, The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan.
Naohide YamashitaDepartment of Advanced Medical Science, The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan.
Osamu KainumaDepartment of Gastroenterological Surgery, Chiba Cancer Center Hospital, Chiba 260-8718, Japan.
Sana YokoiDivision of Translational Genetics, Chiba Cancer Center Research Institute, Chiba 260-8718, Japan.
Yoshiaki MaruDivision of Cancer Genetics, Chiba Cancer Center Research Institute, Chiba 260-8718, Japan.
Hiroki NagaseDivision of Cancer Genetics, Chiba Cancer Center Research Institute, Chiba 260-8718, Japan.
Yoichi FurukawaDivision of Clinical Genome Research, The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan.
Chiba Cancer Center · JPThe University of Tokyo · JPTokyo Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Biliary tract cancer (BTC) is one of the most devastating types of malignant neoplasms worldwide. However, the mechanisms underlying the development and progression of BTC remain unresolved. BTC includes extrahepatic bile duct carcinoma (EBDC), gallbladder carcinoma (GBC) and ampulla of Vater carcinoma (AVC), named according to the location of the tumor. Although genetic alterations of intrahepatic cholangiocarcinoma have been investigated, those of EBDC, GBC and AVC have not yet been fully understood. The present study analyzed somatic mutations of 50 cancer-associated genes in 27 Japanese BTC cells, including: 11 EBDC, 14 GBC and 2 AVC. Next-generation sequencing using an Ion AmpliSeq Cancer Panel identified a total of 44 somatic mutations across 14 cancer-associated genes. Among the 44 mutations, 42 were judged as pathological mutations. Frequent mutations were identified in tumor protein 53 (

Indexed as

ampulla of Vater carcinomabiliary tract cancerextrahepatic bile duct carcinomagallbladder carcinomanext generation sequencingsomatic mutation

Identifiers

PMID28693246
PMCPMC5494721
OpenAlexW2619260554

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.